Alcon to Acquire Belkin Vision for Up to $325 Million

Alcon has enhanced its offerings in glaucoma surgery by announcing its acquisition of Belkin Vision, an Israeli company known for its innovative Eagle SLT laser. This deal is potentially valued at over $300 million, according to reports from the Israel-based business news outlet, Globes.

The report by Globes noted that BioLight Industries, which holds a 4% stake in Belkin Vision, received an immediate payment of NIS 9 million ($2.4 million). Additionally, there could be further milestone payments totaling up to $10.5 million. This sets the total potential value of the deal at around $325 million, including these milestone payments.

Further details regarding the agreement will be revealed following the deal's closure, which is anticipated at the start of the third quarter of 2024.

Belkin received FDA 510(k) clearance for its Eagle device in December. The Eagle is a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser designed for selective laser trabeculoplasty (SLT). It is marketed as the first and only contactless laser for glaucoma treatment, offering an automated and noninvasive approach that benefits both patients and healthcare providers.

*Stay in the loop and make sure not to miss real-time breaking news about ophthalmology. Join our community by subscribing to OBN newsletter now, and get weekly updates.